Predictive value of serum myostatin for the severity and clinical outcome of heart failure

Chen, Pingan; Liu, Zhen; Luo, Yishan; Chen, Lushan; Li, Shaonan; Pan, Yuning; Li, Xiaoming; Wu, Daihong; Xu, Dingli

doi:10.1016/j.ejim.2019.04.017

Cited by 25 publications

(19 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serum BNP levels were shown to be related to cardiovascular dysfunction and disease severity in cirrhosis, (45) while myostatin was proposed to promote cardiomyocyte proteolysis (46) and to have a predictor value for the severity and outcome of heart failure. (47) Moreover, SERCA2, a regulator of intracellular Ca 2+ homeostasis, was down-regulated, which might have contributed to the diastolic dysfunction in BDL. (48) One of the main contributors to BDL-induced liver fibrosis is tissue inflammation, which contributes, as liver failure develops, to the production and excretion of several inflammatory cytokines into the blood, culminating in a general inflammatory response by the body.…”

Section: Discussionmentioning

confidence: 99%

“…These included lower cardiomyocyte diameter alongside smaller heart size and changes in specific markers such as increased serum BNP and myocardial ANP expression (as a sign of heart failure), pathological switch of MHC isoforms, increased AGTR1a, and increased myostatin levels. Serum BNP levels were shown to be related to cardiovascular dysfunction and disease severity in cirrhosis, while myostatin was proposed to promote cardiomyocyte proteolysis and to have a predictor value for the severity and outcome of heart failure . Moreover, SERCA2, a regulator of intracellular Ca 2+ homeostasis, was down‐regulated, which might have contributed to the diastolic dysfunction in BDL…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Interplay of Liver–Heart Inflammatory Axis and Cannabinoid 2 Receptor Signaling in an Experimental Model of Hepatic Cardiomyopathy

et al. 2020

View full text Add to dashboard Cite

Background and Aims Hepatic cardiomyopathy, a special type of heart failure, develops in up to 50% of patients with cirrhosis and is a major determinant of survival. However, there is no reliable model of hepatic cardiomyopathy in mice. We aimed to characterize the detailed hemodynamics of mice with bile duct ligation (BDL)–induced liver fibrosis, by monitoring echocardiography and intracardiac pressure–volume relationships and myocardial structural alterations. Treatment of mice with a selective cannabinoid‐2 receptor (CB2‐R) agonist, known to attenuate inflammation and fibrosis, was used to explore the impact of liver inflammation and fibrosis on cardiac function. Approach and Results BDL induced massive inflammation (increased leukocyte infiltration, inflammatory cytokines, and chemokines), oxidative stress, microvascular dysfunction, and fibrosis in the liver. These pathological changes were accompanied by impaired diastolic, systolic, and macrovascular functions; cardiac inflammation (increased macrophage inflammatory protein 1, interleukin‐1, P‐selectin, cluster of differentiation 45–positive cells); and oxidative stress (increased malondialdehyde, 3‐nitrotyrosine, and nicotinamide adenine dinucleotide phosphate oxidases). CB2‐R up‐regulation was observed in both livers and hearts of mice exposed to BDL. CB2‐R activation markedly improved hepatic inflammation, impaired microcirculation, and fibrosis. CB2‐R activation also decreased serum tumor necrosis factor‐alpha levels and improved cardiac dysfunction, myocardial inflammation, and oxidative stress, underlining the importance of inflammatory mediators in the pathology of hepatic cardiomyopathy. Conclusions We propose BDL‐induced cardiomyopathy in mice as a model for hepatic/cirrhotic cardiomyopathy. This cardiomyopathy, similar to cirrhotic cardiomyopathy in humans, is characterized by systemic hypotension and impaired macrovascular and microvascular function accompanied by both systolic and diastolic dysfunction. Our results indicate that the liver–heart inflammatory axis has a pivotal pathophysiological role in the development of hepatic cardiomyopathy. Thus, controlling liver and/or myocardial inflammation (e.g., with selective CB2‐R agonists) may delay or prevent the development of cardiomyopathy in severe liver disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Interplay of Liver–Heart Inflammatory Axis and Cannabinoid 2 Receptor Signaling in an Experimental Model of Hepatic Cardiomyopathy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A subsequent examination produced findings consistent with early data, demonstrating higher myostatin myocardial expression in HF (although only in females) [ 166 ]. Another research work by Chen et al, found serum myostatin to be higher in chronic HF patients than in healthy controls, higher in non-survivors than in survivors and higher in patients with moderate and high N-terminal pro B-type natriuretic peptide (NT-proBNP) [ 167 ]. The same study demonstrated that high circulating myostatin is a risk factor of chronic HF rehospitalization and an independent predictor of mortality.…”

Section: Factors Affecting Myostatin Concentrationmentioning

confidence: 99%

Myostatin as a Biomarker of Muscle Wasting and other Pathologies-State of the Art and Knowledge Gaps

2020

View full text Add to dashboard Cite

Sarcopenia is a geriatric syndrome with a significant impact on older patients’ quality of life, morbidity and mortality. Despite the new available criteria, its early diagnosis remains difficult, highlighting the necessity of looking for a valid muscle wasting biomarker. Myostatin, a muscle mass negative regulator, is one of the potential candidates. The aim of this work is to point out various factors affecting the potential of myostatin as a biomarker of muscle wasting. Based on the literature review, we can say that recent studies produced conflicting results and revealed a number of potential confounding factors influencing their use in sarcopenia diagnosing. These factors include physiological variables (such as age, sex and physical activity) as well as a variety of disorders (including heart failure, metabolic syndrome, kidney failure and inflammatory diseases) and differences in laboratory measurement methodology. Our conclusion is that although myostatin alone might not prove to be a feasible biomarker, it could become an important part of a recently proposed panel of muscle wasting biomarkers. However, a thorough understanding of the interrelationship of these markers, as well as establishing a valid measurement methodology for myostatin and revising current research data in the light of new criteria of sarcopenia, is needed.

show abstract

“…Myostatin mediates atherosclerotic progress in the abdominal aorta (Verzola et al 2017) and in a recent study in patients with heart failure, higher serum levels of myostatin were found in patients compared to healthy controls. Moreover, in the same study, elevated myostatin levels correlated with the severity of the heart failure and prognosis (Chen et al 2019). Previous data on myostatin and CLL are absent and its role in CLL needs further exploration.…”

Section: Discussionmentioning

confidence: 55%

Increased levels of the cardiovascular disease risk biomarkers GDF15 and myostatin in patients with chronic lymphocytic leukemia

et al. 2020

View full text Add to dashboard Cite

Individuals suffering from cancer, including hematological malignancies, are at increased risk of cardiovascular disease (CVD). Elevated levels of several biomarkers in blood are associated with an increased risk of CVD. The aim of this study was to investigate whether a subset of such CVD risk biomarkers was elevated in patients with untreated chronic lymphocytic leukemia (CLL). Blood plasma and serum from 139 CLL patients and 71 healthy age-matched controls were analyzed for 11 proposed CVD risk biomarkers. The CLL cohort displayed a more heterogeneous pattern of biomarker expression compared to controls. The majority, eight out of 11, analyzed CVD risk biomarkers differed significantly in concentrations between CLL patients and controls. Increased levels of the biomarkers GDF15 and myostatin have not previously been reported in CLL. Further prospective studies are warranted to investigate whether these biomarkers predict future cardiovascular events in patients with CLL.

show abstract

Predictive value of serum myostatin for the severity and clinical outcome of heart failure

Cited by 25 publications

References 39 publications

Interplay of Liver–Heart Inflammatory Axis and Cannabinoid 2 Receptor Signaling in an Experimental Model of Hepatic Cardiomyopathy

Interplay of Liver–Heart Inflammatory Axis and Cannabinoid 2 Receptor Signaling in an Experimental Model of Hepatic Cardiomyopathy

Myostatin as a Biomarker of Muscle Wasting and other Pathologies-State of the Art and Knowledge Gaps

Increased levels of the cardiovascular disease risk biomarkers GDF15 and myostatin in patients with chronic lymphocytic leukemia

Contact Info

Product

Resources

About